PD-L1 overexpression on tumour cells strongly correlates with weaker treatment outcomes and adverse prognosis in gastric cancer, hepatocellular carcinoma, renal cell carcinoma, oesophageal cancer, prostate cancer, and ovarian cancer [38]. The gene discussed is CD274; the disease is prostate cancer.